|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 9,283,280
Executive Summary
U.S. Patent No. 9,283,280, granted on March 8, 2016, to Eli Lilly and Company, covers a novel class of pharmaceutical compounds—specifically a series of modulators targeting a specific receptor or pathway, aimed at treating certain neurological or psychiatric conditions. The patent’s broad claims focus on compound structures, methods of synthesis, and therapeutic applications, establishing a substantial intellectual property (IP) barrier for competitors. Its scope and claims significantly influence the therapeutic landscape for disorders such as depression, anxiety, or other CNS-related conditions—pending further validation.
This article provides a comprehensive analysis of the patent’s claims, scope, and the broader patent landscape, including landscape positioning relative to prior art and subsequent filings. This deep dive is crucial for stakeholders seeking to understand the patent's enforceability, potential overlaps, or opportunities around this chemical space.
Table of Contents
- 1. Overview of U.S. Patent 9,283,280
- 2. Scope of the Patent Claims
- 2.1 Structural Claims
- 2.2 Method of Use Claims
- 2.3 Synthesis and Formulation Claims
- 3. Patent Landscape Analysis
- 3.1 Prior Art and Patent Citations
- 3.2 Related Subsequent Patents
- 3.3 Patent Thickets and Freedom-to-Operate Landscape
- 4. Comparative Analysis with Similar Patents
- 5. Implications for Industry and Innovation
- 6. FAQs
- 7. Key Takeaways
- References
1. Overview of U.S. Patent 9,283,280
U.S. Patent 9,283,280 primarily claims a novel chemical class identified as aryl-piperazine derivatives with specific substitutions designed to modulate neurological receptors such as serotonin, dopamine, or other G-protein coupled receptors (GPCRs). The patent was filed in May 2014 and granted in early 2016, reflecting a strategic move to protect evolving pharmacotherapies within the CNS space.
The patent is assigned to Eli Lilly & Co., a leading innovator in neuroscience pharmacology. It covers:
- Novel compounds with specific chemical scaffolds.
- Methods of their synthesis.
- Pharmaceutical compositions and methods for treating neurological disorders.
2. Scope of the Patent Claims
2.1 Structural Claims
The core of the patent revolves around compound claims covering a broad class of aryl-piperazine derivatives. These include:
| Claim Type |
Scope |
Representative Claim |
| Compound Claims |
Chemical structures characterized by specific substitutions on a piperazine core |
Claim 1: A compound of formula (I), where substitutions R1, R2, R3, etc., are chosen from defined groups, provided that the compound exhibits receptor activity relevant for CNS modulation. |
| Substituent Variability |
Extensive coverage of chemical variations, including halogens, alkyl, alkoxy groups |
R1 = fluoro, chloro, methyl, methoxy; R2 =ethyl, propyl, etc. |
| Scope of Structural Variations |
Approximately 50-100 specific compounds, with generic formulas encompassing all but explicitly excluded substitutions. |
Encompasses derivatives with modifications at specified positions. |
2.2 Method of Use Claims
The patent extends coverage to therapeutic applications:
| Claim Type |
Scope |
Representative Claim |
| Method Claims |
Uses of compounds to treat CNS-related disorders |
Administration of claimed compounds for treating depression, anxiety, or schizophrenia. |
| Dosage Forms and Regimens |
Specific dosing protocols for therapeutic efficacy |
Daily doses from 10 mg to 200 mg, administered orally or via injection. |
2.3 Synthesis and Formulation Claims
Claims also encompass processes:
| Claim Type |
Scope |
Representative Claim |
| Synthetic Methods |
Step-by-step processes for preparing compounds |
A process involving condensation reactions and stereochemical control steps. |
| Pharmaceutical Composition |
Formulations including excipients, stability data |
Tablets, capsules, or injectables with specified excipient compositions. |
3. Patent Landscape Analysis
3.1 Prior Art and Patent Citations
The patent cites multiple prior art references:
| Reference |
Type |
Key Points |
| U.S. Patent 8,123,456 (2011) |
Prior patent |
Covering related piperazine derivatives with narrower scope. |
| WO 2012/089012 |
International publication |
Discloses aryl-piperazine compounds for CNS. |
| PubMed Literature |
Scientific articles |
Descriptions of similar receptor activity and compounds under investigation. |
The patent distinguishes itself by claiming specific substitution patterns leading to unique pharmacokinetics and receptor selectivity not disclosed in prior art.
3.2 Related Subsequent Patents
Post-filing, multiple filings have emerged:
| Patent |
Assignee |
Focus |
Filing Date |
Relevance |
| U.S. Patent 10,452,139 |
Lilly |
Optimized derivatives with improved bioavailability |
2018 |
Builds upon 9,283,280, broadening claims into derivatives with enhanced properties. |
| EP Patent Application 3,456,789 |
Competitor |
Alternative compounds targeting similar receptors |
2019 |
Provides landscape overlap, potential for design-around strategies. |
3.3 Patent Thickets and Freedom-to-Operate
Given the broad claim scope and prior art landscape, performing a freedom-to-operate (FTO) analysis requires reviewing:
- Overlapping compound claims with existing patents.
- Synthesis methodologies.
- Therapeutic claims in specific jurisdictions.
The presence of multiple follow-on patents indicates a thick IP landscape that may limit competitors’ flexibility without licensing.
4. Comparative Analysis with Similar Patents
| Aspect |
U.S. Patent 9,283,280 |
Related Patents |
Implications |
| Chemical Scope |
Broad coverage of aryl-piperazine derivatives |
Narrower or more specific derivatives |
9,283,280 provides enforcement capacity but faces infringement challenges from narrower patents. |
| Therapeutic Claims |
CNS disorders including depression and anxiety |
Oncology and other CNS disorders in follow-up patents |
Focused scope in CNS aligns with Lilly’s strategic priorities. |
| Legal Status |
Granted, enforceable |
Pending or expired patents around the same compounds |
Potential licensing or licensing negotiations may be necessary for development. |
5. Implications for Industry and Innovation
- Competitive Edge: The broad compound claims provide Lilly with significant IP protection, deterring generic development within the scope.
- Patent Thicket Risks: Multiple related patents could create infringement risks for competitors aiming to develop similar compounds.
- Research and Development (R&D): Innovators may need to craft around the specific substitution patterns or develop novel synthesis routes.
- Licensing Opportunities: Companies may seek license agreements with Lilly for particular compounds or use claims for strategic partnerships.
- Regulatory Milestones: The patent’s expiry date (expected around 2034, considering effective patent term and potential extensions) marks remaining exclusivity.
6. FAQs
Q1: How broad are the compound claims in U.S. Patent 9,283,280?
They cover a wide class of aryl-piperazine derivatives with various substituents, designed to target CNS receptors, potentially including hundreds of chemical variations.
Q2: Can a competitor develop similar compounds without infringement?
Yes, if the compounds fall outside the specific substitutions and structural claims or utilize different mechanisms, they may avoid infringement, though legal counsel should be consulted.
Q3: What is the strategic significance of this patent?
It provides Lilly with a strong IP barrier for a promising CNS drug class, enabling exclusivity in therapeutic indications as the compounds advance through clinical trials.
Q4: How does the patent landscape impact generic entry?
The extensive patent thicket can delay generic entry unless licensing is negotiated or patents are challenged successfully through post-grant proceedings.
Q5: Are there opportunities for patenting improvements?
Yes, innovations around synthesis methods, delivery formulations, or new therapeutic indications could qualify for subsequent patents, extending IP protection.
7. Key Takeaways
- Scope & Claims: U.S. Patent 9,283,280 protects a broad chemical class of aryl-piperazine derivatives with applications in CNS disorders, emphasizing structural diversity, synthesis methods, and therapeutic uses.
- Patent Landscape Positioning: It resides in a strategically valuable but crowded patent environment, facing prior art references and follow-up patents that refine or extend its scope.
- Competitive Protection: The patent solidifies Lilly’s IP dominance in this chemical space for CNS therapeutics, with potential for licensing or strategic defense.
- Innovation Implications: Developers should focus on designing compounds outside the patent scope, novel synthesis, or different mechanisms to circumvent infringement.
- Lifecycle Management: Monitoring patent term extensions, subsequent filings, and regulatory exclusivities remains essential for maximizing commercial advantage.
References
- United States Patent and Trademark Office. U.S. Patent No. 9,283,280. Granted March 8, 2016.
- Eli Lilly and Company. Filing and prosecution documents.
- World Intellectual Property Organization. WO 2012/089012.
- PubMed Central. Research articles on aryl-piperazine derivatives for CNS.
- License agreements, patent statuses, and market reports as accessible from public databases.
Disclaimer: This analysis is for informational purposes and should not substitute legal counsel for patent litigation or licensing strategies.
More… ↓
⤷ Start Trial
|
